Literature DB >> 1970265

Carvedilol increases the systemic bioavailability of oral digoxin.

C De Mey1, E Brendel, D Enterling.   

Abstract

The effects of a single oral dose of 25 mg carvedilol on the plasma and urinary kinetics of digoxin after an oral and intravenous 0.5 mg dose, were investigated in two separate double-blind, placebo-controlled, period-balanced cross-over studies in healthy male subjects. Carvedilol increased the mean maximum plasma concentration and the area under the plasma concentration time-curve of digoxin when administered orally. The effects were virtually confined to the first 4 h after dosing, and the apparent terminal disposition rate constant was not changed. Carvedilol did not alter the plasma and urinary kinetics of intravenously administered digoxin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970265      PMCID: PMC1380120          DOI: 10.1111/j.1365-2125.1990.tb03668.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  6 in total

Review 1.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

2.  Letter: Plasma-digoxin concentrations after an intravenous loading dose.

Authors:  A Bertler; B Bergdahl; E Karlsson
Journal:  Lancet       Date:  1974-10-19       Impact factor: 79.321

3.  Generalization of distribution--free confidence intervals for bioavailability ratios.

Authors:  V W Steinijans; E Diletti
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  A simple BASIC program for the calculation of nonparametric confidence intervals in bioequivalence testing.

Authors:  I Meineke
Journal:  Comput Methods Programs Biomed       Date:  1987-02       Impact factor: 5.428

5.  Clinical pharmacology of carvedilol in normal volunteers.

Authors:  L X Cubeddu; N Fuenmayor; F Varin; V G Villagra; R E Colindres; J R Powell
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

6.  Pharmacological profile of carvedilol as a beta-blocking agent with vasodilating and hypotensive properties.

Authors:  G Sponer; W Bartsch; K Strein; B Müller-Beckmann; E Böhm
Journal:  J Cardiovasc Pharmacol       Date:  1987-03       Impact factor: 3.105

  6 in total
  14 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  C J Dunn; A P Lea; A J Wagstaff
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

3.  Lack of a pharmacokinetic interaction between carvedilol and digitoxin or phenprocoumon.

Authors:  S Harder; R Brei; S Caspary; P G Merz
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Differential pharmacokinetics of digoxin in elderly patients.

Authors:  C G Hanratty; P McGlinchey; G D Johnston; A P Passmore
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

Review 5.  Should beta-blockers be used for the treatment of pediatric patients with chronic heart failure?

Authors:  Luke A Bruns; Charles E Canter
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

6.  Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference?

Authors:  Nezihi Baris; Sule Kalkan; Sema Güneri; Volkan Bozdemir; Hulya Guven
Journal:  Eur J Clin Pharmacol       Date:  2006-06-10       Impact factor: 2.953

7.  Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure.

Authors:  Stefanie Albers; Bernd Meibohm; Thomas S Mir; Stephanie Läer
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

Review 8.  Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives.

Authors:  Thomas Unger; Elena Kaschina
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

9.  Captopril does not interact with the pharmacodynamics and pharmacokinetics of digitoxin in healthy man.

Authors:  C de Mey; D Elich; V Schroeter; R Butzer; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

10.  Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate.

Authors:  Ahmed A Othman; David M Tenero; Duane A Boyle; Natalie D Eddington; Michael J Fossler
Journal:  AAPS J       Date:  2007-06-15       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.